Gene amplification-associated overexpression of the RNA editing enzyme ADAR1 enhances human lung tumorigenesis

Oncogene

Volumn 35, Issue 33, 2016, Pages 4407-4413

  Anadon C ^a   Guil, S ^a   Simo Riudalbas L ^a   Moutinho, C ^a   Setien, F ^a   Martinez Cardus A ^a   Moran, S ^a   Villanueva, A ^b   Calaf, M ^b   Vidal, A ^c   Lazo, P A ^d,e   Zondervan, I ^f   Savola, S ^f   Kohno, T ^g   Yokota, J ^g,h   De Pouplana, L R ^i,j   Esteller, M ^a,i,k  

^a HOSPITAL DURAN I REYNALS   (Spain)

^b CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^d UNIVERSITY OF SALAMANCA   (Spain)

^e HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^f MRC HOLLAND   (Netherlands)

^g NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^h Institute of Predictive and Personalized Medicine of Cancer (IMPPC)   (Spain)

ⁱ INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Spain)

^j INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^k UNIVERSITY OF BARCELONA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADAR1 ENZYME; ADENOSINE DEAMINASE; MESSENGER RNA; MICRORNA; MICRORNA 381; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; ADAR1 PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; PROTEIN P21; RNA BINDING PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CELL CULTURE; CELL GROWTH; CELL INVASION; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; GENE AMPLIFICATION; GENE DOSAGE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIVER METASTASIS; LUNG ADENOCARCINOMA; LUNG CANCER CELL LINE; LUNG CARCINOGENESIS; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; PHENOTYPE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; RNA EDITING; GENETICS; LUNG NEOPLASMS; ONCOGENE; TUMOR CELL LINE;

ADENOSINE DEAMINASE; CELL LINE, TUMOR; GENE AMPLIFICATION; HUMANS; LUNG NEOPLASMS; ONCOGENES; PROTO-ONCOGENE PROTEINS P21(RAS); RNA EDITING; RNA-BINDING PROTEINS;

EID: 84949267466     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.469     Document Type: Article

References (23)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics2012. CA Cancer J Clin 2012; 62: 10-29.
2. Buettner R, Wolf J, Thomas RK. Lessons learned from lung cancer genomics: the emerging concept of individualized diagnostics and treatment. J Clin Oncol 2013; 31: 1858-1865.
3. Avesson L, Barry G. The emerging role of RNA and DNA editing in cancer. Biochim Biophys Acta 2014; 1845: 308-316.
4. Li JB, Levanon EY, Yoon J-K, Aach J, Xie B, LeProust E et al. Genome-wide identification of human RNA editing sites by parallel DNA capturing and sequencing. Science 2009; 324: 1210-1213.
5. Peng Z, Cheng Y, Tan BC, Kang L, Tian Z, Zhu Y et al. Comprehensive analysis of RNA-Seq data reveals extensive RNA editing in a human transcriptome. Nat Biotechnol 2012; 30: 253-260.
6. Sakurai M, Ueda H, Yano T, Okada S, Terajima H, Mitsuyama T et al. A biochemical landscape of A-to-I RNA editing in the human brain transcriptome. Genome Res 2014; 24: 522-534.
7. Bazak L, Haviv A, Barak M, Jacob-Hirsch J, Deng P, Zhang R et al. A-to-I RNA editing occurs at over a hundred million genomic sites, located in a majority of human genes. Genome Res 2014; 24: 365-376.
8. Alexandrov LB, Stratton MR. Mutational signatures: the patterns of somatic mutations hidden in cancer genomes. Curr Opin Genet Dev 2014; 24: 52-60.
9. Rommel PC, Bosque D, Gitlin AD, Croft GF, Heintz N, Casellas R et al. Fate mapping for activation-induced cytidine deaminase (AID) marks non-lymphoid cells during mouse development. PLoS One 2013; 8: e69208.
10. Chen L, Li Y, Lin CH, Chan THM, Chow RKK, Song Y et al. Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma. Nat Med 2013; 19: 209-216.
11. Chan THM, Lin CH, Qi L, Fei J, Li Y, Yong KJ et al. A disrupted RNA editing balance mediated by ADARs (Adenosine DeAminases that act on RNA) in human hepatocellular carcinoma. Gut 2014; 63: 832-843.
12. Shoshan E, Mobley AK, Braeuer RR, Kamiya T, Huang L, Vasquez ME et al. Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis. Nat Cell Biol 2015; 17: 311-321.
13. Qin Y-R, Qiao J-J, Chan THM, Zhu Y-H, Li F-F, Liu H et al. Adenosine-to-inosine RNA editing mediated by ADARs in esophageal squamous cell carcinoma. Cancer Res 2014; 74: 840-851.
14. Jiang Q, Crews LA, Barrett CL, Chun H-J, Isquith JM, Zipeto MA et al. ADAR1 promotes malignant progenitor reprogramming in chronic myeloid leukemia. Proc Natl Acad Sci USA 2013; 110: 1041-1046.
15. Sato M, Vaughan MB, Girard L, Peyton M, Lee W, Shames DS et al. Multiple oncogenic changes (K-RASV12, p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. Cancer Res 2006; 66: 2116-2128.
16. Desterro JM, Keegan LP, Lafarga M, Berciano MT, O'Connell M, Carmo-Fonseca M. Dynamic association of RNA-editing enzymes with the nucleolus. J Cell Sci 2003; 116: 1805-1818.
17. Yeo J, Goodman RA, Schirle NT, David SS, Beal PA. RNA editing changes the lesion specificity for the DNA repair enzyme NEIL1. Proc Natl Acad Sci USA 2010; 107: 20715-20719.
18. Daniel C, Ven MT, Ekdahl Y, Kjems J, Ohman M. A distant cis acting intronic element induces site-selective RNA editing. Nucleic Acids Res 2012; 40: 9876-9886.
19. Skalsky RL, Cullen BR. Reduced expression of brain-enriched microRNAs in glioblastomas permits targeted regulation of a cell death gene. PLoS One 2011; 6: e24248.
20. Liu M, Doublie S, Wallace SS. Neil3, the final frontier for the DNA glycosylases that recognize oxidative damage. Mutat Res 2013; 743-744: 4-11.
21. Formosa A, Markert EK, Lena AM, Italiano D, Finazzi-Agro E, Levine AJ et al. MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR- -487b, miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32. 31 locus, regulate proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells. Oncogene 2014; 33: 5173-5182.
22. Wang Z, Yang J, Xu G, Wang W, Liu C, Yang H et al. Targeting miR-381-NEFL axis sensitizes glioblastoma cells to temozolomide by regulating stemness factors and multidrug resistance factors. Oncotarget 2015; 6: 3147-3164.
23. Wilkerson MD, Yin X, Walter V, Zhao N, Cabanski CR, Hayward MC et al. Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylation. PLoS One 2012; 7: e36530.